The beta thalassemia testing market is projected to grow from USD 564.4 million in 2025 to USD 1,241.3 million by 2035, at a CAGR of 8.2%. Next-Generation Sequencing will dominate with a 48.6% market share, while prenatal testing will lead the test type segment with a 44.2% share.